ADVERTISEMENT

Stay up to date every week with the european biotechnology newsletter.

✕

X/Twitter

This field is for validation purposes and should be left unchanged.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

Stay up to date every week with the european biotechnology newsletter.

Log in here to read the desired article.

Instagram

This field is for validation purposes and should be left unchanged.

Email(Required)

This field is hidden when viewing the form

EBcom NL

confirm list

This field is hidden when viewing the form

Consent

I agree to the privacy policy.

go to the article

go back to the homepage

Subscription
Newsletter
Advertise

Latest news
Background
Opinion
The Mag
Euro Biotech Guide
Market Place
Associations
Service
Events
Search
Menu Menu

ADVERTISEMENT

SPONSORED PUBLICATIONS

Humanized NSG and NSG-SGM3 mice as a new preclinical bridge for immune-oncology therapies.

Page 24 of 24«‹22 2324

LATEST NEWS

birch tree pollen

Desentum secures €28M for faster allergy immunoth...

Karen Massey, CEO of argenx

What’s next for argenx, Europe’s autoimmune bre...

Photo: Getty Images for Unsplash+

Newron plans heart tests to lift schizophrenia tria...

ADVERTISEMENT

MAGAZINE

1 / 4

EBM 3.2026 Autumn_cover

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

4 / 4

EB425_Cover

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

SPONSORED PUBLICATION

1 / 3

Celonic

Perfusion for next generation biosimilars

Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially … more ➔

2 / 3

eppendorf-new_CDMO115x65V2

Every process is different. Not the platform.

For CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales. more ➔

3 / 3

Professor Jacob George, Chief Medical and Scientific Officer at the MHRA presenting his keynote speech at Phacilitate Advanced Therapies Europe, 2026

Cell & Gene Therapy

Europe’s CGT advantage at risk

Industry leaders at Advanced Therapies Europe 2026 warned that Europe must tackle barriers across commercialisation, regulation, reimbursement, manufacturing and patient access to retain its global … more ➔

newsletter_link

Knowbio GmbH

Link to LinkedIn
Link to Instagram

Contact
Imprint
Privacy policy